Palabras clave
Hígado graso
Cirrosis hepática
Fibrosis
Síndrome X metabólico Gastroenterology
Fatty liver
Non-alcoholic fatty liver disease
Liver cirrhosis
Fibrosis
Metabolic syndrome X
Cómo citar
Resumen
Introducción: La enfermedad hepática grasa no alcohólica o hígado graso, es una de las principales causas de enfermedad hepática a nivel mundial, con una prevalencia aproximada al 30% en adultos. Esta condición se ha asociado como factor de riesgo independiente para la presentación de eventos cardiovasculares y la aparición de diabetes. En nuestro medio no se conocen las características clínicas de los pacientes con diagnóstico de hígado graso. Objetivo: describir las características clínicas de 115 pacientes con diagnóstico de hígado graso que consultaron al servicio de hepatología de la Clínica Universitaria Colombia durante el periodo de estudio, en Bogotá. Metodología: revisión de historias clínicas de pacientes con diagnóstico de hígado graso de la consulta externa de hepatología de la Clínica Universitaria Colombia, desde el 1 de enero de 2010 hasta el 31 de mayo de 2013, describiendo las características clínicas y la asociación con enfermedades metabólicas y cardiovasculares. Resultados: se revisó retrospectivamente la historia clínica de 115 Pacientes. 54,8% eran mujeres y 45,2% hombres, la edad promedio de diagnóstico fue de 54 años. El antecedente de importancia con más frecuencia fue la dislipidemia, la cual se presentó en 57 pacientes (49%). Conclusiones: el diagnóstico de hígado graso se establece en cerca de un 20% de los pacientes que acuden a una consulta especializada de hepatología. Llama la atención que el 24% de los pacientes debuta en forma de cirrosis y se encuentra una asociación clara con el síndrome metabólico e hígado graso en nuestra serie, lo que concuerda con la literatura internacional.
Citas
Ludwig J et al. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55:434-8.
McCallough A. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis. 2004 ;8(3):521-33. https://doi.org/10.1016/j.cld.2004.04.004
N. Mavrogiannaki and I. N. Migdalis, Nonalcoholic Fatty Liver Disease, Diabetes Mellitus and Cardiovascular Disease: Newer Data, International Journal of Endocrinology, Volume 2013. https://doi.org/10.1155/2013/450639
Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-1395. https://doi.org/10.1002/hep.20466
Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2004; 40:578. https://doi.org/10.1016/j.jhep.2004.02.013
Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9:524. https://doi.org/10.1016/j.cgh.2011.03.020
Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21:17. https://doi.org/10.1055/s-2001-12926
Arun J, Clements RH, Lazenby AJ, et al. The prevalence of nonalcoholic steatohepatitis is greater in morbidly obese men compared to women. Obes Surg 2006; 16:1351. https://doi.org/10.1381/096089206778663715
Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37:917. https://doi.org/10.1053/jhep.2003.50161
Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140:124. https://doi.org/10.1053/j.gastro.2010.09.038
Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34:274. https://doi.org/10.1111/j.1365-2036.2011.04724.x
M.H. Ahmed and C. D. Byrne, "Metabolic syndrome, diabetes & CHD risk," in The Year in Lipid Disorders, C. J. Packard, Ed.,pp. 3-26, Clinical Publishing, Oxford, UK, 2007.
Gaggini Melania, Morelli Mariangela, Buzzigoli Emma, DeFronzo A Ralph, Bugianesi Elisabetta, Gastaldelli Amalia, Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease, Nutrients 2013, 5, 1544-1560. https://doi.org/10.3390/nu5051544
P. H. Chiang, T. Y. Chang, and J. D. Chen, "Synergistic effect of fatty liver and smoking on metabolic syndrome," World Journal of Gastroenterology, vol. 15, no. 42, pp. 5334-5339, 2009. https://doi.org/10.3748/wjg.15.5334
Bashar M Attar, David H Van Thiel, Current Concepts and Management Approaches in Nonalcoholic Fatty Liver Disease, The Scientific World Journal, 2013. https://doi.org/10.1155/2013/481893
A. N. Mavrogiannaki and I. N. Migdalis, Nonalcoholic Fatty Liver Disease, Diabetes Mellitus and Cardiovascular Disease: Newer Data, International Journal of Endocrinology, Volume 2013. https://doi.org/10.1155/2013/450639
Wen-Shan Lv, Rui-Xia Sun, Yan-Yan Gao, JunPing Wen, Rong-Fang Pan, Li Li, Jing Wang, et al. Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes, World J Gastroenterol 2013 May 28; 19(20): 3134-3142. https://doi.org/10.3748/wjg.v19.i20.3134
Jun DW The Role of Diet in Non-alcoholic Fatty Liver Disease. Korean J Gastroenterol. 2013 May 25; 61(5):243-51. https://doi.org/10.4166/kjg.2013.61.5.243
Marchesini G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003; 37(4):917-23. https://doi.org/10.1053/jhep.2003.50161
Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999- 2008. JAMA 2010; 303:235- 241. https://doi.org/10.1001/jama.2009.2014
Ahmed MH, Barakat S, Almobarak AO. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists? J Obes. 2012; 2012:483135. https://doi.org/10.1155/2012/483135
S. Bellentani, G. Saccoccio, F.Masutti et al., "Prevalence of and risk factors for hepatic steatosis in Northern Italy," Annals of Internal Medicine, vol. 132, no. 2, pp. 112-117, 2000. https://doi.org/10.7326/0003-4819-132-2-200001180-00004
A. L. Fracanzani, L. Valenti, E. Bugianesi et al., "Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes," Hepatology, 2008, (3); 792-798. https://doi.org/10.1002/hep.22429
Gastaldelli, A.; Cusi, K.; Pettiti, M.; Hardies, J.; Miyazaki, Y.; Berria, R.; Buzzigoli, E.; Sironi, A.M.; Cersosimo, E.; Ferrannini, E.; et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007, 133, 496-506. https://doi.org/10.1053/j.gastro.2007.04.068
Bhatia, L.S.; Curzen, N.P.; Calder, P.C.; Byrne, C.D. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur. Heart J. 2012, 33, 1190-1200. https://doi.org/10.1093/eurheartj/ehr453
K.Cusi, "the role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes", Current Diabetes Reports. 2010 (10); 306-315. https://doi.org/10.1007/s11892-010-0122-6
R. N. Rahman and J. A. Ibdah, "Nonalcoholic fatty liver disease without cirrhosis is an emergent and independent risk factor of hepatocellular carcinoma: a population based study", Hepatology, 2012.
Brunt EM, Tiniakos DG. Alcoholic and nonalcoholic fatty liver disease. In Surgical pathology of the GI tract, liver, biliary tract and pancreas, 2nd ed., Odze RD, Goldblum JR. (Eds), Elsevier, Philadelphia 2009. p.1007.
Charatcharoen witthaya P, Lindor KD, Angulo P. The spontaneous course of liver enzymes and its correlation in nonalcoholic fatty liver disease. Dig Dis Sci 2012; 57:1925. https://doi.org/10.1007/s10620-012-2098-3
Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: An eleven-year follow-up study. Am J Gastroenterol 2009; 104(4): 861-7. https://doi.org/10.1038/ajg.2009.67
Mohammad Ebrahim Ghamar-Chehreh, Mohsen Amini, Hossein Khedmat, Seyed Moayed Alavian, Fatemeh Daraei, Reza Mohtashami, et al. Elevated alanine aminotransferase activity is not associated with dyslipidemias, but related to insulin resistance and higher disease grades in non-diabetic nonalcoholic fatty liver disease, Asian Pac J Trop Biomed 2012; 2(9): 702-706. https://doi.org/10.1016/S2221-1691(12)60213-5
Kowdley KV, Belt P, Wilson LA, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012; 55:77. https://doi.org/10.1002/hep.24706
Tae Hoon Lee, Han H Seung, Yang D Ju, Kim Donghee, Monjur Ahmed, Prediction Of Advanced Fibrosis in non alcoholic Fatty Liver Disease: An Enhaced Model of BARD Score, Gut and Liver, 2013, (7); 323-328. https://doi.org/10.5009/gnl.2013.7.3.323
Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 2010;55:560-578. https://doi.org/10.1007/s10620-009-1081-0
N. Chalasani, Z. Younossi, J. E. Lavine et al., "The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association", &e American Journal of Gastroenterology, 2012; 811-826. https://doi.org/10.1053/j.gastro.2012.04.001
M. H. Ahmed, "Biochemical markers: the road map for the diagnosis of nonalcoholic fatty liver disease", American Journal of Clinical Pathology, vol. 127, no. 1, pp. 20-22, 2007. https://doi.org/10.1309/JXWUM661T8VT1ETX
Sánchez Santiago, Huertas Sandra, Prieto Jhon, Características clínicas y de respuesta al tratamiento en pacientes con hepatitis c crónica de la Clínica Universitaria Colombia y un servicio de consulta externa de hepatología Bogotá D.C. 2009 - 2012, Rev. Medica.Sanitas 16 (1): 18-25, 2013."